# Co-treatment With Pegvisomant and a Somatostatin Analogue (SA) in SA-responsive Acromegalic Patients

> **NCT00652379** · NA · COMPLETED · sponsor: **University of Aarhus** · enrollment: 18 (actual)

## Conditions studied

- Acromegaly
- Insulin Resistance
- Impaired Glucose Tolerance

## Interventions

- **DRUG:** Pegvisomant
- **DRUG:** Somatostatin analog (lanreotide or octreotide)

## Key facts

- **NCT ID:** NCT00652379
- **Lead sponsor:** University of Aarhus
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06
- **Primary completion:** 2009-11
- **Final completion:** 2011-05
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2012-01-26

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00652379

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00652379, "Co-treatment With Pegvisomant and a Somatostatin Analogue (SA) in SA-responsive Acromegalic Patients". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT00652379. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*